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Rapid Hepatobiliary Excretion of 
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Upconverting Nanoparticles as an 
Integrated Form
Hyo Jung Seo1,3,*, Sang Hwan Nam4,*, Hyung-Jun Im1,3,*, Ji-yong Park3, Ji Youn Lee3, 
Byeongjun Yoo5,6, Yun-Sang Lee1,3, Jae Min Jeong3, Taeghwan Hyeon5,6, Ji Who Kim3, 
Jae Sung Lee3, In-Jin Jang2, Joo-Youn Cho2, Do Won Hwang1,3, Yung Doug Suh4,7 & 
Dong Soo Lee1,3
In the field of nanomedicine, long term accumulation of nanoparticles (NPs) in the mononuclear 
phagocyte system (MPS) such as liver is the major hurdle in clinical translation. On the other hand, 
NPs could be excreted via hepatobiliary excretion pathway without overt tissue toxicity. Therefore, 
it is critical to develop NPs that show favorable excretion property. Herein, we demonstrated that 
micelle encapsulated 64Cu-labeled upconverting nanoparticles (micelle encapsulated 64Cu-NOTA-
UCNPs) showed substantial hepatobiliary excretion by in vivo positron emission tomography (PET) 
and also upconversion luminescence imaging (ULI). Ex vivo biodistribution study reinforced the 
imaging results by showing clearance of 84% of initial hepatic uptake in 72 hours. Hepatobiliary 
excretion of the UCNPs was also verified by transmission electron microscopy (TEM) examination. 
Micelle encapsulated 64Cu-NOTA-UCNPs could be an optimal bimodal imaging agent owing to 
quantifiability of 64Cu, ability of in vivo/ex vivo ULI and good hepatobiliary excretion property.
Although nanoparticles (NPs) have a huge potential as both diagnostic imaging and therapeutic agents, a 
majority of attempt for clinical translation has been blocked by unsolved biocompatibility issues. Indeed, 
delayed excretion and non-biodegradability of NPs have caused overt toxicity and tissue damage1–5. Many 
reports demonstrated that NPs are persistently taken by the mononuclear phagocyte system (MPS) and 
induce tissue toxicity in liver and spleen3,6. One the other hand, by modifying surface characteristics, 
NPs could be excreted via hepatobiliary excretion pathway without overt tissue toxicity7,8. Therefore, it 
is critical to develop the biocompatible NPs that show favorable excretion property to minimize toxicity 
in vivo9.
Micelle encapsulation method for hydrophilization of nanomaterials was first described by Dubertret 
et al.10 and further refined by several groups11–13. Recently, our group integrated the method and pro-
posed one-step method under mild conditions to preserve ligand integrity to make functionally active 
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multi-specific nanoparticles14. However, biodistribution and excretion pattern of micelle encapsulated 
nanoparticle was not well evaluated until now. Especially, whether the integral nanoparticle or disinte-
grated parts are excreted and whether even the post-administration aggregation influences the biodistri-
bution pattern have not been well elucidated.
Upconverting nanoparticles (UCNPs) have recently received interest for their in vivo imaging capabil-
ity that can emit visual light upon absorption of long wavelength near-infrared (NIR) photons. Indeed, 
upconversion luminescence imaging (ULI) may provide the advantages of autofluorescence-free nature15, 
good penetration depth, and low photodamage in cells16. Also, to enhance water solubility and biocom-
patibility, surface coating of UCNP using phospholipid has been reported17. Positron emission tomogra-
phy (PET) has been considered as useful imaging modality for biodistribution study with high sensitivity, 
depth penetration and capability of quantification18.
In the present study, we demonstrated the micelle-encapsulated labeling method of a bimodal imag-
ing agent, and that the biodistribution and excretion of these NPs are favorable as the platform for in 
vivo use using in vivo PET and ULI. We reinforced imaging results by ex vivo biodistribution study and 
feces evaluation, and finally explored the mechanism of hepatobiliary excretion by transmission electron 
microscopy (TEM) of the liver.
Results
Synthesis of micelle encapsulated 64Cu-NOTA-UCNPs. The entire labeling method of micelle 
encapsulated 64Cu-NOTA-UCNPs was illustrated in Fig. 1a. UCNPs showed hexagonal shape on TEM, 
and were not changed after micelle encapsulation (Fig. 1b). The micelle encapsulated UCNPs in phos-
phate buffer solution (PBS) showed visible green light by 980-nm laser excitation (Fig. 1c). Using micelle 
encapsulation method, the radiochemical purity of micelle encapsulated 64Cu-NOTA-UCNPs was higher 
than 99%. The mode size of micelle encapsulated UCNPs, and micelle encapsulated 64Cu-NOTA-UCNPs 
were 34.1 ± 6.4 nm and 34.4 ± 2.6 nm, respectively (Fig. 1d,e). The zeta potential of micelle encapsulated 
UCNPs and micelle encapsulated 64Cu-NOTA-UCNPs were − 27.1 ± 5.43 mV and − 6.63 ± 6.31 mV, 
respectively.
In vivo PET Imaging of micelle encapsulated 64Cu-NOTA-UCNPs. In vivo PET images were 
acquired serially after intravenous administration of micelle encapsulated 64Cu-NOTA-UCNPs via tail 
vein injection (Fig. 2a). Initially, tracer uptake was shown primarily in the liver and the lungs at 0.25 hour 
PET image. Hepatic uptake persisted until 8 hours. At 1 hour, uptake in the intestine was observed and 
extended downstream along the intestine at 2, 4 and 8 hours. Interestingly, uptakes in the liver mark-
edly decreased at 24 hours compared to 8 hours, and this decreased further until 72 hours (Fig. 2a). The 
serial PET images indicated that micelle encapsulated 64Cu-NOTA-UCNPs were excreted by hepato-
biliary system on visual inspection. The amount of radioactivity in each organ which was quantified 
by region of interest analysis was consistent with the visual findings (Fig. 2b). The ex vivo biodistribu-
tion data were also consistent with quantified PET data that the concentration of micelle encapsulated 
64Cu-NOTA-UCNPs in the liver decreased further until 72 hours. 84% of the initial hepatic uptake was 
excreted at 72 hours. Meanwhile, the concentration of micelle encapsulated 64Cu-NOTA-UCNPs in the 
intestine increased in small intestine first and then large intestine, and decreased at 24 hours due to the 
expulsion of feces (Fig. 2c).
Free 64Cu or 64Cu-NOTA-C18 are not likely detached from micelle encapsulated 64Cu-NOTA- 
UCNPs in vivo. To examine the possibility of the detachment of free 64Cu or 64Cu-NOTA-alkyl chain 
(64Cu-NOTA-C18) from the injected micelle encapsulated 64Cu-NOTA-UCNPs, PET images using free 
64Cu (n = 3) or 64Cu-NOTA-C18 (n = 3) were acquired. 64Cu or 64Cu-NOTA-C18 showed different biodis-
tribution from micelle encapsulated 64Cu-NOTA-UCNPs in in vivo PET image (Supplementary Fig. 1a). 
64Cu-NOTA-C18 showed initial high bladder activity at 0.25 hr image, indicating rapid renal excretion 
which is minimal in micelle encapsulated 64Cu-NOTA-UCNPs. Absence of initial bladder uptake of the 
micelle encapsulated 64Cu-NOTA-UCNPs support that 64Cu-NOTA-C18 was not detached from them which 
is understandable considering the size of the UCNPs19. Both micelle encapsulated 64Cu-NOTA-UCNPs 
and 64Cu-NOTA-C18 showed initial higher hepatic uptake and faster excretion than free 64Cu. Also, 
free 64Cu activity in heart persisted until 24 hours unlike 64Cu-NOTA-C18 and micelle encapsulated 
64Cu-NOTA-UCNPs, probably due to recirculation of the copper ion20 (Supplementary Fig. 1b). Free 
64Cu or 64Cu-NOTA-C18 were not likely detached from the micelle encapsulated 64Cu-NOTA-UCNPs in 
vivo. In one recent report, 111In-DOTA was detached in vivo from the 111In-DOTA-amphiphile encapsu-
lated Au particles and excreted via kidneys21, which is in contrast to our findings. What determines in 
vivo detachment of chelators from the amphiphiles, i.e., nature of the core, nature of the amphiphile, or 
the chemical bond between chelator and amphiphile, is to be understood.
In vivo luminescence imaging shows pattern of hepatobiliary excretion. Luminescence 
imaging of UCNPs was done at serial time points using in-house built apparatus. In in vivo and in 
situ luminescence imaging, initial liver uptake at 1 hour decreased faster at further time points than 
in PET (Fig.  3a). This apparent rapid disappearance of luminescence signal was probably due to lim-
ited depth-penetrance of luminescence signals emitted from the UCNPs in the hepatic porta and the 
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Figure 1. Synthesis and characterization of micelle encapsulated 64Cu-NOTA-UCNP. (a) Polysorbate 
60 was used to transfer the hydrophobic UCNPs into aqueous phase and NOTA-C18 was used for the 
radiolabeling. Then, 64Cu was added and labeled with NOTA-UCNPs. Enlarged configuration of micelle 
encapsulated 64Cu-NOTA-UCNP was included. Compounds including UCNP, polysorbate 60, NOTA-C18, 
oleic acid and 64Cu are listed in the blue box. (b) TEM image of UCNPs before (left) and after (right) 
micelle encapsulation (c), Upconversion luminescence image of UCNPs under 980 nm laser excitation. 
(d,e) Size of micelle encapsulated NOTA-UCNPs (d) and micelle encapsulated 64Cu-NOTA-UCNPs 
(e) measured by nanoparticle tracking analysis (NTA) method showing sharp peak which indicates 
uniform size of the nanoparticles. Size of micelle encapsulated 64Cu-NOTA-UCNPs showed similar size 
with the micelle encapsulated NOTA-UCNPs.
www.nature.com/scientificreports/
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Figure 2. In vivo whole body microPET imaging and biodistribution study in micelle encapsulated 64Cu-
NOTA-UCNPs-injected mice. (a) Decay-corrected MIP (Maximum Intensity Projection) images at different 
time points after intravenous injection of micelle encapsulated 64Cu-NOTA-UCNPs. Hepatic uptake was 
increased until 2 hours delay image, and then decreased serially. The blood pool activity was visualized in 
heart, lungs and both kidneys at 0.25 hour image and disappeared at 1 hour delay image. Segmental uptake 
in the intestine was noted after 1 hour. The linear intestinal uptake was seen until 8 hours and was minimal 
at 24 hours after injection. (b) Quantitative analysis of in vivo PET image in mice after intravenous injection 
of micelle encapsulated 64Cu-NOTA-UCNPs. The data corresponded to visual analysis of the PET images. 
(c) Ex vivo biodistribution in mice after intravenous injection of micelle encapsulated 64Cu-NOTA-UCNPs. 
Data (n = 3) were expressed as mean ± SD, indicating the percentage administered activity (injected dose) 
total gram of tissue (% ID/g). The uptake of liver markedly decreased at 24 hours. Radioactivity of intestine 
increased until 8 hours and decreased at 24 hours. MeanSUV in (b) represents mean standardized uptake 
value. Error bars in (b,c) correspond one standard deviation.
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intestines. At 1 hour ex vivo image, liver, spleen and lungs showed signals reminding consistent ex vivo 
biodistribution results (Fig. 3b). The intestinal luminescence by UCNPs was clearly seen after exposure 
of intestinal contents (Fig.  3c). This intestinal uptake was prominent until 8 hours delay, which was in 
accordance with the in vivo PET and ex vivo biodistribution studies showing hepatobiliary excretion. ULI 
imaging in situ after animal sacrifice complied well with PET images and their quantification results as 
well as ex vivo biodistribution data.
Integral 64Cu-NOTA-UNCPs are excreted to feces and urine. For further verification of the 
hepatobiliary excretion of the micelle encapsulated 64Cu-NOTA-UNCPs, we collected feces and urine. 
Percentage of injected dose (%ID) in all of the collected feces and urine were calculated based on gamma 
scintillation analysis and the values were 40.9 ± 3.3, 1.1 ± 0.6%, respectively until 24 hour. Intense PET 
and upconversion luminescence signals were observed in most of the feces (Fig. 4a,b). On microscopic 
ULI, multiple scattered UCNP particles were found in the feces by their luminescence (Fig. 4b). Although 
in very small amount, urinary excretion of UCNP was confirmed by luminescence images, showing that 
Figure 3. In vivo upconversion luminescence images in nude mice. (a) In vivo and in situ images at 
different time points. Upconversion luminescence signal was visualized in the liver area at 1 hour after the 
injection and disappeared in in vivo image. In in situ images, upconversion luminescence signal in the liver 
was shown and decreased until 8 hours delay images and it was not seen on 24 hours delay image. (b) Ex 
vivo upconversion luminescence image at 1 hour image showed positive signals in the lungs, liver and spleen. 
(c) Four hours after the injection, multifocal luminescence signals could be seen along the lumen of the 
intestine. All images were acquired under the same experimental condition.
www.nature.com/scientificreports/
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Figure 4. Evidences of hepatobiliary and urinary excretion using multimodal imaging and methods. (a) PET 
image showed increased uptake in collected feces. All feces (n = 3) showed heterogeneously increased uptake. 
Yellow circles with numbers indicate that the feces were from different mice. (b) Upconversion luminescence 
images of feces at serial time points. Upconversion luminescence signal was observed in all collected feces after 
4 hour post-injection. Microscopic image shows multiple and scattered UCNPs. (c) Upconversion luminescence 
imaging (ULI) of collected urine at 30 minutes after 64Cu-NOTA-UNCP injection. Several spots with 
luminescence were observed inside of tube. Enlarged image shows multiple UCNPs.
www.nature.com/scientificreports/
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spotty signal (Fig.  4c). We now know that integral 64Cu-NOTA-UNCPs were excreted mainly by feces 
and also by urine in small amount. It seems that the amount in urine was too small to be visualized 
in in vivo PET imaging (Fig.  2a, Supplementary Fig. 1a). There were several reports showing urinary 
excretion of nanoparticles with larger size than the pore of the glomerulus, however, the mechanism is 
not clear now22.
Biliary excretion of UCNPs is revealed by TEM. For mechanistic understanding of hepatobiliary 
excretion, TEM study was done using liver section of mice sacrificed at 1 hour (n = 3) and 24 hours 
(n = 3) after injection of micelle encapsulated 64Cu-NOTA-UCNPs. Normal structure of sinusoid and 
hepatocyte is demonstrated in Fig. 1a. At 1 hour, UCNPs was observed inside of sinusoid (Fig. 5b), space 
of Disse (Fig. 5c,d), Kupffer cells (Fig. 5e,f) and hepatocytes (Fig. 5g,h). Inside the hepatocytes, UCNPs 
are localized in cytoplasmic vesicles and some of the vesicles contained multiple UCNPs (Fig.  5g,h). 
Also, UCNPs were found in bile canaliculi which is an initial pathway of bile excretion (Fig.  5i,j). At 
24 hours after injection, interestingly, UCNPs were observed in Kupffer cells but not inside of hepato-
cytes (Fig. 5k,l). These findings suggest that injected UCNPs were endocytosed by either hepatocytes or 
Kupffer cells in the liver and UCNPs in the hepatocytes were excreted via biliary excretion pathway. On 
the contrary, UCNPs in the Kupffer cells seem to remain inside these cells until 24 hours after injection 
(Fig. 6). The very small amounts of UCNPs on nanoparticle tracking analysis measurements with larger 
size indicating aggregates might explain the activity of UCNP aggregates taken up by the Kupffer cells 
(Figs 1e and 5l).
Discussion
As in our ex vivo biodistribution results, over 80% clearance from initial liver uptake within 72 hours is 
quite substantial compared to previous reports showing hepatobiliary excretion of NPs7,8,23. Generally, 
nanoparticles with larger size than glomerulus pore initially retained in liver or spleen after intravenous 
administration24. After the NPs have reached to the liver, the NPs were considered to be endocytosed 
mainly by Kupffer cells or possibly by hepatocytes. NPs endocytosed by hepatocytes will enhance hepa-
tobiliary excretion19. To be endocytosed by hepatocyte, size of NP should have been less than 100 nm 
because the size of fenestration of endothelium of the liver is around 100 nm24. Also, size around 50 nm is 
optimal to maximize the rate of endocytosis in several types of NPs25. Thus size of NP of the present study 
(34.4 nm) might have been optimal for hepatobiliary excretion. And/or micelle encapsulation of the nan-
oparticle should have facilitated hepatobiliary excretion. There were several earlier reports that showed 
hepatobiliary excretion of liposome26 and micelles27,28. In accordance with the reports, 64Cu-NOTA-C18, 
which would have formed micelles in the aqueous solvent, also showed substantial hepatobiliary excre-
tion after initial urinary excretion. We suggest that micelle encapsulated 64Cu-NOTA-UNCPs are notified 
as micelles to the liver thus, more prone to be taken up by hepatocyte rather than Kupffer cell. Also, 
micelle encapsulation could lower the protein adsorption to NPs, thus lower the chance of phagocyto-
sis by Kupffer cells29,30. Obviously, PEGylation and low surface negative charge of micelle encapsulated 
64Cu-NOTA-UCNPs were necessary, though not sufficient, for substantial hepatobiliary excretion of the 
NPs. PEGylation and low surface charge of NPs are also known to reduce protein adsorption in serum 
and phagocytosis19,31. Accordingly, the rate of endocytosis of the NPs to hepatocytes could increase.
We found that 16% of the initial hepatic uptake of the micelle encapsulated 64Cu-NOTA-UNCPs 
remained in the liver at 72 hours after the injection. The remained NPs were probably to have been 
phagocytosed by Kupffer cells and thus not likely to be excreted via hepatobiliary excretion even after 
72 hours. Because UCNPs were only seen in Kupffer cells at 24 hours after the injection (Fig. 5k,l) and 
there was no discrete uptake in the intestinal excretion from 24 hours after the injection (Fig. 2a). Also 
our speculation is supported by the previous knowledge that once NPs are phagocytosed by Kupffer cell, 
the NPs will be retained in the cells unless the NPs are broken down by intracellular process19.
Using NPs in human body is a very challenging goal. Even though large amount of the UCNPs was 
excreted in the present study, we could not exclude the possibility of long term adverse health effect by 
the remained UCNPs. Using the amount of the UCNPs as low as possible could be one way to further 
lower the possible toxicity9,32.
In vivo imaging using UCNPs is still quite challenging because the depth of tissue penetration is still 
limited. Optical imaging property of UCNPs was very helpful to confirm the excretion pattern in the 
present study, however to use the UCNPs based NPs for a generalized in vivo imaging agent, the NPs 
and imaging tool should be further optimized. Using UCNPs with more penetrable excitation light33 or 
applying further surface coating to lower quenching by water molecule34 could be ways to improve in 
vivo imaging ability of UCNPs.
In the present study, micelle encapsulated 64Cu-NOTA-UNCPs showed 75% of serum stability at 
24 hours. 25% of instability in the human serum of the micelle encapsulated 64Cu-NOTA-UNCPs might 
be caused by protein adsorption to the NPs which could alter metabolic pathway of the NPs. However, 
according to PET image and biodistribution data in the present study, the NPs cleared from blood pool 
within 1 hour and observed serum stability of the micelle encapsulated 64Cu-NOTA-UCNPs was almost 
100% until 4 hours. Thus we could assume that protein adsorption on the NPs would not significantly 
change the metabolic pathway of the micelle encapsulated 64Cu-NOTA-UCNPs.
www.nature.com/scientificreports/
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Figure 5. Observation of hepatobiliary excretion on TEM study. (a) Structure of hepatocytes and sinusoid 
is demonstrated. Black fenestrated lines are delineating sinusoid space. At 1 hour after injection of UCNPs, 
UCNPs were observed inside of sinusoid (b) and in the space of Disse (c,d) (d) = magnified image of white 
box area in (c). Multiple UCNPs were found in the intracellular space of Kupffer cell which is lying on 
sinusoid lining (e,f) (f) = magnified image of white box area in (e). UCNPs were found in cytoplasm of 
hepatocyte in vesicular structure (g,h) (h) = magnified image of white box area in (g). UCNPs were found 
inside the bile canaliculi (i,j) (j) = magnified image of white box area in (i). At 24 hours after injection 
of UCNPs, UCNP was not seen in hepatocyte (k) but seen in Kupffer cell (l). Arrows indicate UCNPs. 
Asterisks (*) indicate red blood cells. Crosses (†) indicate nuclei of hepatocytes.
www.nature.com/scientificreports/
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In conclusion, we demonstrated feasibility of bimodal in vivo imaging characteristics of micelle encap-
sulated 64Cu-NOTA-UCNP and showed the substantial hepatobiliary excretion through in vivo micro-
PET, ULI, and ex vivo biodistribution study. We also confirmed that our micelle encapsulation method 
worked and its product 64Cu-NOTA-UCNP distributed in vivo as integral entity which finally excreted 
by hepatobiliary routes. Thus, we propose that micelle encapsulated 64Cu-NOTA-UCNP exploiting its 
multiplexing capabiltiy, by adding further functional moiety, could be used for bimodal targeting agent 
for simultaneous ULI and PET study for variety of purposes, for example, radio-theranostic UCNP with 
multiplexed targeting ligands and chelator for therapeutic 177Lu.
Materials and Methods
Chemicals. YCl3∙6 H2O (99.9%), YbCl3∙6H2O (99.9%), ErCl3∙6H2O (99.9%), oleic acid (technical grade, 
90%), 1-octadecene (technical grade, 90%) and NH4F (98.0%) were purchased from Aldrich. Sodium 
oleate was purchased from TCI. 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyeth-
yle-ne glycol)-2000] (mPEG-2000 PE) was purchased from Avanti Polar Lipids, Inc. All reagents were 
used as received.
Synthesis of hexagonal phase NaYF4:Yb3+/Er3+ nanoparticles (UCNPs). The hexagonal UCNPs 
were synthesized as described in a report by Li et al.35. Y-oleate, Yb-oleate and Er-oleate complexes were 
prepared by the methods reported previously36. Briefly, 0.78 mmol of Y-oleate, 0.2 mmol of Yb-oleate 
and 0.02 mmol of Er-oleate complexes were mixed with 10 mL of oleic acid and 15 mL of 1-octadecene 
in a 100 mL three-neck round bottom flask. And the reaction mixture was heated up to 100 °C under 
vacuum with stirring for 30 min to remove residual water and oxygen and then cooled the solution to 
room temperature. 10 mL of methanol solution containing 2.5 mmol of NaOH and 4 mmol of NH4F was 
slowly added into the reaction vessel under Ar. The reaction mixture was stirred for 30 min at 50 °C. The 
reaction mixture was heated to 100 °C under vacuum with stirring for 30 min to remove methanol. Then 
the reaction mixture was heated to 300 °C at a constant heating rate of 3.3 °C/min, and then kept at that 
temperature for 1 hour under Ar. The resulting solution was then cooled at room temperature. No further 
purification was needed and the UCNPs showed uniform size of 28 × 34 nm which was measured from 
TEM images using ImageJ software (NIH). Concentration and composition of UCNPs were analyzed by 
inductively coupled plasma mass spectrometer (ICP-MS, ELAN 6100, Perkin Elmer) to be 113.88 nM and 
Y:Yb:Er = 86.5:12.4:1.1 (mol%), respectively.
Synthesis of chelating agent conjugated with stearyl chains (NOTA-C18). 1-(p-benzyl-1′ , 
4′ ,7′ -triazacyclononane-1′ ,4′ ,7′ -triacetic acid)-3-octadecylthiourea (NOTA-C18) for 64Cu labeling was 
synthesized by conjugating 2-(p-isothiocyanatobenzyl)-1,4,7-triazacyclononane-1,4,7-triacetic acid 
(SCN-Bn-NOTA) and stearylamine. SCN-Bn-NOTA (20 mg, 0.04 mmol) was dissolved in CHCl3 (1 mL), 
and TEA (0.012 mL, 0.09 mmol) was added and stirred at room temperature. Stearylamine (14 mg, 
0.05 mmol) was then added to the reaction mixture and stirred for 20 hours. The product was purified 
by the column chromatography on silica-gel (230–400 mesh) with CH2Cl2:MeOH (9:1) mixture as a 
eluent. The structure was confirmed by mass spectroscopy. Yield: 26 mg (72%). Mass spectrum (ESI + ), 
(M+H+): 821.8. HRMS (M+H+): observed 720.4731, calculated 720.4734.
Encapsulation of UCNPs with amphiphiles. The synthesis of water-soluble UCNPs was followed by 
the previous protocol14. Polysorbate 60 was the only commercially available (Sigma-Aldrich) amphiphile 
used in this study. 4% (v/v) polysorbate 60 solution in distilled water (1 mL) was added to NOTA-C18. 
The mixture was then heated to 80 °C at 20 min.
Figure 6. Schematic presentation of the kinetics of UCNPs in the liver tissue. Injected UCNPs reach 
sinusoid, which is a fenestrated capillary, via portal venule. In sinusoid, UCNPs can be phagocytosed by 
Kupffer cells or filtered out to space of Disse and endocytosed by hepatocytes. Endocytosed UCNPs to 
hepatocytes can go to biliary canaliculi and are excreted via biliary excretion pathway. This figure was drawn 
by Do Won Hwang and Hyung-Jun Im.
www.nature.com/scientificreports/
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After the removal of hexane from UCNPs with inert gas, functionalized amphiphiles (2% [mol/mol] 
of polysorbate 60) were added. The mixture was sonicated for 80 min using VialTweeter at UIS250v at 
~84.5 watt (Hielscher Ultrasonics GmbH, Germany). The reaction mixtures containing UCNPs were 
applied to a Sephacryl S-400 column (Sigma-Aldrich) (6.7 × 150 mm) and eluted with distilled water to 
remove unbound polysorbate 60 and other amphiphiles. Fractions (1 mL) were collected and concen-
trated by ultrafiltration (Amicon Ultracel, 100-kDa cutoff; Millipore).
Size measurement by nanoparticle tracking analysis. The size distribution was checked by the 
nanoparticle tracking analysis (NTA) method using a NanoSight NS500 (Malvern, Grovewood road, UK) 
by using minor modification of manufacturer’s methods. Samples were diluted sufficiently for the con-
trast and minimal background level. The quick measurement mode was performed to find the optimal 
condition. Then, total 5 numbers of particle motion video were recorded automatically using standard 
measurement mode (temperature: 20.3 or 20.4 °C and viscosity: 0.99 to 1.0 cP). All other conditions were 
constant.
64Cu radiolabeling. 64Cu was produced from cyclotron PETtrace 10 (GE healthcare, Sweden). The 
micelle encapsulated NOTA-UCNPs (32 pmol, 10 μ L) was mixed with 64CuCl2 (5–6 mCi/0.1 mL) in the 
presence of 1 M sodium acetate buffer (pH 5.6, 0.3 mL). Then the reaction mixture was incubated for 
10 min at 45 °C. The labeling yield was determined by ITLC-SG (1 × 10 cm strip) eluted with 0.1 M citric 
acid. The ITLC-SG strip was scanned using a TLC scanner. For the in vivo study, micelle encapsulated 
64Cu-NOTA-UCNPs was concentrated using an Amicon filtration system (Millipore).
Stability test. The stabilities of micelle encapsulated 64Cu-NOTA-UCNPs (0.37 MBq) in 
phosphate-buffered saline at room temperature and in human serum at 37 °C were determined by 
instant thin-layer chromatography-silica gel (ITLC-SG) plates (Pall Corp., U.S.A.) with 0.1 M cit-
ric acid at 0, 10, 30, 60 min and 2, 4, 8, 24 hours. The ITLC-SG strip was scanned using a TLC scan-
ner (AR-2000, Bioscan, U.S.A.). Micelle encapsulated 64Cu-NOTA-UCNPs were stable for more than 
24 hours in phosphate-buffered saline at room temperature (100%) and in human serum at 37 °C (75%) 
(Supplementary Fig. 2).
In vivo microPET imaging of micelle encapsulated 64Cu-NOTA-UCNPs, 64Cu-NOTA and free 
64Cu injected mice. Specific pathogen-free 6-week-old male BALB/c mice were obtained from 
SLC Inc. (Japan). All of the animal experiments were approved by Institutional Animal Care and Use 
Committee of the Clinical Research Institute at Seoul National University Hospital and performed in 
accordance with the guideline from the institute. In addition, the National Research Council guidelines 
for the care and use of laboratory animals (revised 1996) were observed throughout.
Using micelle encapsulated 64Cu-NOTA-UCNPs and animal PET (GENISYS, Sofie Biosciences, Culver 
City, CA), the biodistribution study in BALB/c mice was evaluated. After 64Cu -NOTA-UCNPs were 
injected to the tail vein of mice (weight = 24.1 ± 0.5 g, dose = 40 ± 0.6 μ Ci/50 μ L), animal PET was per-
formed to obtain serial time point images (0.25, 1, 2, 4, 8, and 24 hours, n = 5/0.25, 1, 2, 4, 8, 24, 48 and 
72 hours, n = 4). Images were acquired for 15 minutes until 24 hours, and acquired for 30 and 60 minutes 
at 48 hours, and 72 hours respectively. For the comparison study of free 64Cu (n = 3), 64Cu-NOTA-C18 
(n = 3) and micelle encapsulated 64Cu-NOTA-UCNPs (n = 9), BALB/c mice were prepared. Dose of 
64Cu was 35 μ Ci/50 μ L (19.9 g) and dose 64Cu-NOTA-C18 was 40 μ Ci/50 μ L (18.6 g) by tail vein injec-
tion before PET image acquisition. Dynamic whole-body PET images were obtained during 15 min in 20 
frames (10 × 60 s). The images were obtained by 3-dimensional Fourier rebinning using a 2-dimensional 
ordered-subsets expectation maximization reconstruction algorithm with scatter, decay, and attenua-
tion correction from raw framed sonograms. In each PET image, 3-dimensional regions of interest were 
drawn over major organs on whole-body axial images. Mean standardized uptake values (meanSUV) 
were obtained using PMOD software from reconstructed data. Animal PET was performed serially at 
30 min, after injection under isoflurane inhalation anesthesia. After acquisition of 24 hours delayed PET 
image, mice were sacrificed. All liver and spleen were fixed in formaline solution. Feces and urine of mice 
after injection of micelle encapsulated 64Cu-NOTA-UCNPs were evaluated by PET image to confirm the 
excretion of micelle encapsulated 64Cu-NOTA-UCNPs. The biodistribution and microPET experiments 
were performed in Seoul National University Hospital, which is fully accredited by AAALAC International 
(2007, Association for Assessment and Accreditation of Laboratory Animal Care International).
Biodistribution study using micelle encapsulated 64Cu-NOTA-UCNPs and ex vivo method. All 
mice used were male BALB/c mouse (4 ~ 5 weeks old) obtained from the breeding facility of the Seoul 
National University Hospital Biomedical Research Institute. Micelle encapsulated 64Cu-NOTA-UCNPs 
were injected into a male BALB/c mouse via the tail vein (weight = 20.1 g, dose = 1 μ Ci/100 μ L). The 
injected mice were sacrificed in serial time points (1, 4, 8, 24, and 72 hours, 3 mice for collection of feces 
and urine, n = 3, respectively, total n = 18) of post-injection. Blood, liver, muscle, kidney, lung, heart, small 
intestine, large intestine, bone and other organs were then excised, blotted and weighed, and then 64Cu 
radioactivity of each organ was counted by a gamma scintillation counter (DREAM r-10, Shinjin Medics 
Inc., South Korea). The results are expressed as percentages of injected doses per gram of tissue (%ID/g).
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Preparation of intraluminal feces, feces and urine smear section for upconverting lumines-
cence imaging. Whole large and small intestine of BALB/c nude mouse after 8 hours injection of 
UCNPs was cut about 3 cm size and each resected intestine was put on the slide glass. For reducing 
penetration scattering of photoluminescence, we dissected intestinal lumen vertically in every 3 cm size 
intestine. The specimens were extended on the slide glass and the other glass was compressed. Feces were 
collected for the serial time point. Individual feces was compressed and enlarged by the slide glass for the 
better optical image. Spotty urine from mice after 30 min and 1 hour injection of UCNPs was collected 
and normal saline only was mixed for the slide glass smear. Photoluminescence imaging of feces and 
urine were obtained, respectively.
Upconverting luminescence spectra of UCNPs. In-house made optical imaging apparatus 
for in vivo UCNP imaging was used. The UCNP solutions were excited by 980-nm CW laser (SDL-
980LM-500 T, Shanghai Dream Lasers Technology) and the emission was collected at right angle by 
an optical fiber and detected by a CCD camera (PIXIS 400BR, Princeton Instruments) attached to a 
monochromator (HoloSpec f/1.8, Kaiser Optical Systems). It was composed of an inverted microscope 
(TE2000-U, Nikon), an NIR (980 nm) diode laser (P161-600-980 A, EM4), and an electron multiplying 
CCD (EMCCD) camera (DV897DCS-BV, iXon, Andor Technology). The output of the 980 nm laser 
was reflected by a short-pass dichroic beam splitter (725dcspxr, Chroma Technology) and directed to 
the microscope objective (Plan Apo VC, 60X, NA 1.40, oil immersion, Nikon). The beam was focused 
on the back focal plane of the objective by a planoconvex lens (focal length 400 mm) resulting in the 
illumination area with diameter of ca. 60 mm. The typical power density of illumination was 300 W/
cm2 on the sample surface. The emission from the UCNPs in the visible range was collected by the 
same objective, passed through the dichroic beam splitter and a short-pass emission filter (ET700sp-2p, 
Chroma Technology), magnified further by a set of achromatic lenses outside the microscope, and finally 
imaged by the EMCCD camera. The transmission range of the emission filter (400–700 nm) covers both 
the green (centered at 525 and 545 nm) and red (centered at 657 nm) emission bands from UCNPs. We 
also obtained bright field images of feces and urine samples using the same EMCCD camera and a lamp 
as the light source.
Acquisition of upconversion luminescence imaging. The in vivo upconversion luminescence 
imaging in BALB/c nude mice was performed after tail vein injection of UCNPs (weight = 24.1 g, 
dose = 0.12 mg/300 μ L, total n = 7). Injection dose was escalated from 40 ug/mouse, and starting at the 
dose of 158 ug/mouse, we could obtain sufficient signals for in vivo luminescent imaging which is 13 
times higher amount than that for the dose of PET imaging (12 μ g/mouse). Before the image acquisition, 
peritoneal anesthesia in mice was performed. In vivo photoluminescence imaging was obtained as serial 
time points (1, 2, 4, 8, and 24 hours). For in situ image, nude mouse skin and peritoneum was exfoliated. 
After sacrifice, ex vivo image was performed. All images were acquired under the same experimental con-
dition (980 nm laser power = 21 W (30 A), ~300 mW/cm2, EMCCD Gain = 250, exposure time = 10 s).
Acquisition of TEM. TEM images were taken at an acceleration voltage of 80 keV (JEM-1400; Jeol). 
To obtain negative-stain TEM images of UCNPs and micelle encapsulated UCNPs, UCNPs solutions 
were dropped onto a Formvar carbon-coated copper grid (SPI-Chem) and stained with saturated uranyl 
acetate solution. To observe hepatobiliary excretion, liver specimen was carefully selected. Liver tissue 
from micelle encapsulated 64Cu-NOTA-UCNPs injected mice was chopped and multiple pieces were 
selected including 5 regions of both lobes of liver, 1 hour (n = 3) and 24 hours after injection (n = 4).
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